Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23364135 | 1.00 | DUT (0.37) | DUTPDK2 | |
| SCHEMBL5676651 | 0.85 | PDK2 (0.37) | DUTPDK2 | |
| SCHEMBL5676774 | 0.85 | PDK2 (0.37) | DUTPDK2 | |
| SCHEMBL22029081 | 0.85 | PDK2 (0.37) | DUTPDK2 | |
| SCHEMBL21552650 | 0.81 | PTGER2 (0.33) | DUT | |
| SCHEMBL21552619 | 0.81 | PTGER2 (0.33) | DUT | |
| SCHEMBL21552649 | 0.81 | PTGER2 (0.33) | DUT | |
| SCHEMBL24851540 | 0.78 | ATM (0.34) | DUT | |
| SCHEMBL21565343 | 0.78 | ATM (0.34) | DUT | |
| SCHEMBL28526715 | 0.78 | ATM (0.34) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| EP-4058455-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003675-A | Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097116-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | DUT 2029/4885PDK2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.